These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23045428)

  • 1. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
    Ménard J; Rigel DF; Watson C; Jeng AY; Fu F; Beil M; Liu J; Chen W; Hu CW; Leung-Chu J; LaSala D; Liang G; Rebello S; Zhang Y; Dole WP
    J Transl Med; 2014 Dec; 12():340. PubMed ID: 25491597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
    Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF
    Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.
    Schumacher CD; Steele RE; Brunner HR
    J Hypertens; 2013 Oct; 31(10):2085-93. PubMed ID: 24107737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review.
    Wang HZ; Tian JB; Yang KH
    Eur Rev Med Pharmacol Sci; 2015; 19(2):296-304. PubMed ID: 25683946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
    Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
    Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
    Cai TQ; Stribling S; Tong X; Xu L; Wisniewski T; Fontenot JA; Struthers M; Akinsanya KO
    J Pharmacol Toxicol Methods; 2015; 71():137-46. PubMed ID: 25304940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study.
    Andersen K; Hartman D; Peppard T; Hermann D; Van Ess P; Lefkowitz M; Trapani A
    J Clin Hypertens (Greenwich); 2012 Sep; 14(9):580-7. PubMed ID: 22947355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of targeting CYP11B.
    Bernhardt R
    Expert Opin Ther Targets; 2016 Aug; 20(8):923-34. PubMed ID: 26854589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates.
    Weldon SM; Cerny MA; Gueneva-Boucheva K; Cogan D; Guo X; Moss N; Parmentier JH; Richman JR; Reinhart GA; Brown NF
    J Pharmacol Exp Ther; 2016 Oct; 359(1):142-50. PubMed ID: 27481775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
    Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
    J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone synthase inhibition in hypertension.
    Andersen K
    Curr Hypertens Rep; 2013 Oct; 15(5):484-8. PubMed ID: 23917810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.
    Papillon JP; Lou C; Singh AK; Adams CM; Ksander GM; Beil ME; Chen W; Leung-Chu J; Fu F; Gan L; Hu CW; Jeng AY; LaSala D; Liang G; Rigel DF; Russell KS; Vest JA; Watson C
    J Med Chem; 2015 Dec; 58(23):9382-94. PubMed ID: 26540564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450.
    Valentín-Goyco J; Liu J; Peng HM; Oommen J; Auchus RJ
    J Steroid Biochem Mol Biol; 2023 Jul; 231():106316. PubMed ID: 37098354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism.
    Amar L; Azizi M; Menard J; Peyrard S; Plouin PF
    J Hypertens; 2013 Mar; 31(3):624-9; discussion 629. PubMed ID: 23314743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
    Cerny MA; Csengery A; Schmenk J; Frederick K
    J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
    Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
    Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
    J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.